Vagus nerve stimulation does not lead to significant changes in body weight in patients with epilepsy

被引:30
作者
Koren, MS
Holmes, MD [1 ]
机构
[1] Univ Washington, Dept Neurol, Reg Epilepsy Ctr, Seattle, WA 98195 USA
[2] Univ Washington, Dept Med, Div Endocrinol, Seattle, WA USA
关键词
appetite; regulation; seizures; adverse effects; energy balance; vagus nerve stimulation; refractory epilepsy;
D O I
10.1016/j.yebeh.2005.10.001
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Background. Vagus nerve stimulation (VNS) is an FDA-approved treatment for medically intractable epilepsy. The effect of this therapy on body weight is unclear. VNS could cause weight loss by engaging vagal afferents from the gastrointestinal tract mediating satiety. Methods. We performed a retrospective analysis of body weight changes over a period up to 2 years following VNS implantation. We studied 21 patients (13 M/8 F) 35 +/- 12 years old, who received a Cyberonics VNS Therapy System for medically intractable epilepsy between April 1998 and May 2004. The mean SD duration of follow-up was 613.1 +/- 389.1 days. The study had 80% power with a type I error of 0.05 to detect a 5% weight change. Data were analyzed with repeated-measures ANOVA. Results. Weight changes relative to baseline at 30, 60, 120, 360, 480, and 720 days were -0.17 +/- 2.33, +0.33 +/- 2.64, -0.32 +/- 3.56, +1.09 +/- 5.97, +1.06 +/- 7.47, and +0.33 +/- 3.69%, respectively. At all time points these differences failed to reach statistical significance. Conclusions. Vagus nerve stimulation with parameters typically used in the treatment of patients with epilepsy was not associated with clinically significant weight changes. A well-controlled prospective study is necessary for more precise evaluation of the effect of VNS therapy on body weight. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:246 / 249
页数:4
相关论文
共 25 条
[1]   Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction [J].
Andrews, PLR ;
Sanger, GJ .
CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (06) :650-656
[2]  
Balbo SL, 2000, RES COMMUN MOL PATH, V108, P291
[3]   MEAL PATTERNS AND PLASMA LIVER-ENZYMES AND METABOLITES AFTER TOTAL LIVER DENERVATIONS [J].
BELLINGER, LL ;
WILLIAMS, FE .
PHYSIOLOGY & BEHAVIOR, 1995, 58 (03) :625-628
[4]   Weight loss associated with vagus nerve stimulation [J].
Burneo, JG ;
Faught, E ;
Knowlton, R ;
Morawetz, R ;
Kuzniecky, R .
NEUROLOGY, 2002, 59 (03) :463-464
[5]   Canine vagus nerve stores cholecystokinin-58 and-8 but releases only cholecystokinin-8 upon electrical vagal stimulation [J].
Chang, TM ;
Thagesen, H ;
Lee, KY ;
Roth, FL ;
Chey, WY .
REGULATORY PEPTIDES, 2000, 87 (1-3) :1-7
[6]   Gastric pacing for morbid obesity: Plasma levels of gastrointestinal peptides and leptin [J].
Cigaina, V ;
Hirschberg, AL .
OBESITY RESEARCH, 2003, 11 (12) :1456-1462
[7]   Gastric pacing as therapy for morbid obesity: Preliminary results [J].
Cigaina, V .
OBESITY SURGERY, 2002, 12 (Suppl 1) :12S-16S
[8]   Celiac vagotomy reduces suppression of feeding by jejunal fatty acid infusions [J].
Cox, JE ;
Tyler, WJ ;
Randich, A ;
Kelm, GR ;
Meller, ST .
NEUROREPORT, 2001, 12 (06) :1093-1096
[9]   The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats [J].
Date, Y ;
Murakami, N ;
Toshinai, K ;
Matsukura, S ;
Niijima, A ;
Matsuo, H ;
Kangawa, K ;
Nakazato, M .
GASTROENTEROLOGY, 2002, 123 (04) :1120-1128
[10]   POWER AND SAMPLE-SIZE CALCULATIONS - A REVIEW AND COMPUTER-PROGRAM [J].
DUPONT, WD ;
PLUMMER, WD .
CONTROLLED CLINICAL TRIALS, 1990, 11 (02) :116-128